All Articles
Biotech

Amber Bio Raises $26 Million For Undruggable Diseases

August 5, 2023
x min read
Amber Bio Raises $26 Million For Undruggable Diseases

Amber Bio, a San Francisco based developer of gene editing platforms to reach undruggable diseases, announced $26M in funding from a16z, Playground Global, Eli Lilly, Hummingbird Ventures and Pillar VC.

The big idea:

  • Amber Bio is developing an innovative RNA editing platform that aims to correct genetic mutations in a safe, reversible way
  • If successful, the technology would be able to edit thousands of of different, diverse mutations across patients with one single product
  • Current gene editing technology treats one single genetic mutation at a time, which is not scaleable for patients

Discover the world's most disruptive early stage companies with 25,000+ investors.

The markets and trends that matter, made simple.

Join top talent at the world's most respected institutions, companies, and venture capital funds.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.